Application of programmed death 1 inhibitors in Hodgkin lymphoma / 白血病·淋巴瘤

ABSTRACT

The programmed death-1 (PD-1) inhibitor has a unique mechanism and better efficacy in classic Hodgkin lymphoma (cHL). Multiple PD-1 inhibitors have been approved for the salvage treatment of patients with cHL in advanced stage. The combination of PD-1 with other small molecule targeted drugs, immunoactive drugs or cytotoxic drugs can further improve the efficacy and have a better safety compared with the traditional treatment, meanwhile, the regimens have also been explored in treatment of recurrent and refractory patients and frontline therapy. In addition, 9P24.1 amplification, PD-1 ligand expression and circulating tumor DNA level may be potential biomarkers for predicting the efficacy of PD-1 inhibitors.